MedPath

In-situ Cytokines Expression in the CNS in Amyotrophic Lateral Sclerosis (ALS)

Completed
Conditions
Amyotrophic Lateral Sclerosis
Registration Number
NCT02582385
Lead Sponsor
Brugmann University Hospital
Brief Summary

The investigators aim at exploring the differential/topographical in-situ expression of cytokines in the central nervous system (CNS) of patients who died with amyotrophic lateral sclerosis (ALS), using archived histopathology slides and residual paraffin blocks from autopsied cases. Previous studies from the investigators and other groups showed that inflammatory cytokines are implicated in several neurological affections, particularly neurodegenerative conditions. However, in-situ cytokine expression has never been studied so far in ALS. The investigators wanted to see if these neuro-mediators are involved in the neuromolecular chain/cascade underlying ALS.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
5
Inclusion Criteria
  • patients who died with amyotrophic lateral sclerosis, having been autopsied.
Exclusion Criteria
  • N/A

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
in situ cytokine detection: interleukin 18retrospective study performed on archived paraffin blocks, autopsies performed between 2000 and 2005

IHC detection on histopathology sections of paraffin embedded brain tissue.

in situ cytokine detection: interleukin 1retrospective study performed on archived paraffin blocks, autopsies performed between 2000 and 2005

IHC detection on histopathology sections of paraffin embedded brain tissue.

in situ cytokine detection: interleukin 6retrospective study performed on archived paraffin blocks, autopsies performed between 2000 and 2005

IHC detection on histopathology sections of paraffin embedded brain tissue.

in situ cytokine detection:TNF-aretrospective study performed on archived paraffin blocks, autopsies performed between 2000 and 2005

IHC detection on histopathology sections of paraffin embedded brain tissue.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

CHU Brugmann

🇧🇪

Brussels, Belgium

CHU Brugmann
🇧🇪Brussels, Belgium

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.